Introgen Therapeutics (INGNQ) 8-K Introgen Therapeutics Reports Third Quarter 2005 Financial Results

Exhibit 99.1

FOR IMMEDIATE RELEASE

Introgen Therapeutics Reports Third Quarter 2005 Financial Results

Results in Line with Expectations

AUSTIN, TX, November 9, 2005— Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today its results for the quarter ended September 30, 2005, reporting progress during the period in its research and development and clinical trial programs and an alliance with Colgate-Palmolive Co.

In November 2005, Introgen formed an alliance with Colgate-Palmolive Co. to develop and potentially market oral healthcare products. Introgen received $20 million from the sale of common stock to Colgate-Palmolive, which increased Introgen’s cash balance to approximately $40 million.

Introgen reported a net loss of $6.1 million, or $0.18 per share, for the quarter ended September 30, 2005. These results compare to a net loss of $7.1 million, or $0.23 per share, for the previous quarter ended June 30, 2005 and a net loss of $7.0 million, or $0.26 per share, for the comparable prior year quarter ended September 30, 2004.

During the quarter ended September 30, 2005, Introgen used cash, cash equivalents and short-term investments of $5.1 million to conduct its operations and used $3.0 million for an equity investment in SR Pharma plc. Introgen’s cash, cash equivalents, marketable securities and short-term investments, were $22.6 million at September 30, 2005. Revenue was $398,000 for the quarter ended September 30, 2005, compared to revenue of $336,000 for the quarter ended June 30, 2005 and $209,000 for the quarter ended September 30, 2004. Operating expenses were $6.7 million for the quarter ended September 30, 2005, compared to $7.7 million for the quarter ended June 30, 2005 and $7.4 million for the quarter ended September 30, 2004.

For the nine months ended September 30, 2005, Introgen reported a net loss of $19.4 million, or $0.61 per share, compared to a net loss for the nine months ended September 30, 2004 of $20.0 million, or $0.75 per share. Revenue for the nine months ended September 30, 2005 was $1.2 million, compared to revenue for the nine months ended September 30, 2004 of $592,000. Operating expenses were $21.5 million for the nine months ended September 30, 2005 compared to $21.3 million for the nine months ended September 30, 2004.

Quarterly Conference Call
Introgen has scheduled a conference call to discuss the financial results at 4:30 p.m. eastern time today. Interested parties can access a live Internet broadcast at www.introgen.com. The call may also be accessed by dialing 1-877-616-4476 or 1-706-679-7372. For those unable to listen to the broadcast the call will be archived at Introgen’s Website in the Investor Relations section.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development program for treatment of cancer or other diseases and Introgen’s financial performance and the future success of Introgen’s alliance with Colgate-Palmolive Co. to potentially market oral healthcare products. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

###

Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website atwww.introgen.com.

Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com

INTROGEN THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET

	SEPTEMBER 30,		DECEMBER 31,
	2005		2004
	(Unaudited)
	(Thousands)
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		18,606		38,180
MARKETABLE SECURITIES		4,023		—
OTHER CURRENT ASSETS		338		659
PROPERTY AND EQUIPMENT, NET		6,565		7,277
GRANT RIGHTS ACQUIRED		870		1,582
OTHER ASSETS		334		359
TOTAL ASSETS	$	30,736	$	48,057
ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES	$	6,524	$	6,858
NOTES PAYABLE, NET OF CURRENT PORTION		7,946		7,901
OTHER LONG TERM LIABILITIES		1,336		1,132
TOTAL LIABILITIES		15,806		15,891
TOTAL STOCKHOLDERS’ EQUITY		14,930		32,166
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	30,736	$	48,057

INTROGEN THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)

	THREE MONTHS ENDED						NINE MONTHS ENDED
	SEPTEMBER 30,						SEPTEMBER 30,
	2005			2004			2005			2004
	(Thousands except per share information.)
CONTRACT SERVICES, GRANT AND OTHER REVENUE	$	398		$	209		$	1,243		$	592
OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT		5,090			5,734			16,029			15,977
GENERAL AND ADMINISTRATIVE		1,657			1,710			5,473			5,302
TOTAL OPERATING EXPENSES		6,747			7,444			21,502			21,279
LOSS FROM OPERATIONS		(6,349	)		(7,235	)		(20,259	)		(20,687	)
INTEREST INCOME, INTEREST EXPENSE AND OTHER INCOME, NET		285			214			903			668
NET (LOSS)		($6,064	)		($7,021	)		($19,356	)		($20,019	)
NET LOSS PER SHARE, BASIC AND DILUTED		($0.18	)		($0.26	)		($0.61	)		($0.75	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER SHARE		33,394			26,703			31,782			26,626